Viatris Inc
VTRS: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$21.00 | Tqlr | Dyhvnhmft |
Viatris Posts Modest Decline in Third Quarter Against Competitive Pressures
Viatris had an unremarkable third quarter, posting a modest year-over-year decline, spread evenly among its product categories. Revenue was slightly subdued by competitive pressures in contrast with a strong prior quarter. It is expected that the long-term erosion of generic drug revenue will be irregular quarter to quarter and dependent on each manufacturer’s product mix. We maintain our $25 fair value estimate for no-moat Viatris.